|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Hepatitis B in China
Datamonitor, Feb 2011, Pages: 123
Introduction
Fuelled by the increasing use of new, expensive drugs, and the anticipated launch of new therapies, the Chinese HBV drugs market, sized at $227m in 2009, will triple in size by 2019. The market will see a significant shift in brand use: older drugs like lamivudine or adefovir dipivoxil will lose market share to newer treatments, including entecavir, tenofovir, and PEGylated interferon therapies.
Features and benefits
- In-depth analysis of the current Chinese hepatitis B market situation.
- Detailed sales and volume forecasts for key hepatitis B drug classes, molecules and brands in the Chinese market.
- Thorough assessment of underlying commercial and clinical influencers shaping the Chinese hepatitis B market.
- In-depth discussion of novel hepatitis B pipeline candidates and assessment of their future potential in China.
Highlights
- Small molecule antiviral drugs held the lion share of the Chinese hepatitis B market in terms of sales in 2009, generating sales of $200.1m and growing at a CAGR of 57.4% between 2006–09. The use of both small molecule antivirals and interferons has increased over the past 4 years, while traditional Chinese medicine only plays a minor role.
- Multinational corporations dominate the Chinese hepatitis B market. In 2009, five foreign pharmaceutical companies accounted for 45.7% of total sales volume and 76.1% of total sales value in the Chinese hepatitis B market, while 26 domestic players competed for the remaining market share.
- Viread (tenofovir; GlaxoSmithKline) and Levovir (clevudine; Eisai Pharmaceuticals) are expected to be approved by the Chinese State Food and Drug Administration for the treatment of hepatitis B in 2014 and 2016, respectively. Viread will play a game-changer role in the Chinese hepatitis B competitive landscape
Your key questions answered
- Gain insight through a detailed sales forecast and a thorough analysis of marketed and pipeline products for hepatitis B in China.
- Understand where concerns, unmet needs and future opportunities lie by learning about the views of Chinese key hepatitis B opinion leaders.
- Review the clinical and commercial factors driving new product decisions in hepatitis B, and the opportunities and threats shaping the Chinese market.
|
|
|
|
